Results 271 to 280 of about 440,409 (317)
Some of the next articles are maybe not open access.
Atherosclerosis, 2018
During their metabolism, all lipoproteins undergo endocytosis, either to be degraded intracellularly, for example in hepatocytes or macrophages, or to be re-secreted, for example in the course of transcytosis by endothelial cells. Moreover, there are several examples of internalized lipoproteins sequestered intracellularly, possibly to exert ...
Paolo Zanoni+4 more
openaire +4 more sources
During their metabolism, all lipoproteins undergo endocytosis, either to be degraded intracellularly, for example in hepatocytes or macrophages, or to be re-secreted, for example in the course of transcytosis by endothelial cells. Moreover, there are several examples of internalized lipoproteins sequestered intracellularly, possibly to exert ...
Paolo Zanoni+4 more
openaire +4 more sources
The Biochemistry of Lipoproteins
Journal of Inherited Metabolic Disease, 1988SummaryLipids are transported in the blood in four major classes of lipoproteins. The triacylglycerol‐rich lipoproteins are chylomicrons and very‐low‐density lipoproteins (VLDL) which are produced by the small intestine and liver, respectively. These lipoproteins mainly carry fatty acids to adipose tissue and muscle where the triacylglycerol is ...
David N. Brindley, Andrew M. Salter
openaire +3 more sources
Baillière's Clinical Endocrinology and Metabolism, 1995
Lipoprotein (a) is similar to low-density lipoprotein but is unique in having an additional apolipoprotein called apolipoprotein (a) (apo(a)) covalently linked to it. apo(a), which is a member of the plasminogen gene superfamily, has a protease domain which cannot be activated to cause fibrinolysis.
openaire +2 more sources
Lipoprotein (a) is similar to low-density lipoprotein but is unique in having an additional apolipoprotein called apolipoprotein (a) (apo(a)) covalently linked to it. apo(a), which is a member of the plasminogen gene superfamily, has a protease domain which cannot be activated to cause fibrinolysis.
openaire +2 more sources
Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease
Journal of Clinical Lipidology, 2019Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD). In the United States, lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany uses LA therapy for patients with an Lp(a) > 60 mg/dL, normal low-density lipoprotein cholesterol (LDL-C) levels, and CVD.
Patrick M. Moriarty+2 more
openaire +3 more sources
European Journal of Cardiovascular Prevention & Rehabilitation, 1994
Our understanding of the pathophysiological role of lipoprotein (a) in cardiovascular disease and its clinical importance has improved, but there are still gaps in our knowledge and analytical performance that hinder the appropriate management of patients.
openaire +2 more sources
Our understanding of the pathophysiological role of lipoprotein (a) in cardiovascular disease and its clinical importance has improved, but there are still gaps in our knowledge and analytical performance that hinder the appropriate management of patients.
openaire +2 more sources
β-lipoprotein, lipoprotein lipase and atromid
Journal of Atherosclerosis Research, 1963Summary The lipoprotein lipase activity eluted in connection with chromatographically separated β-lipoprotein was considerably lower in 6 cases of essential hyperlipaemia than the average for 7 healthy controls. Atromid administration seemed to increase the lipoprotein lipase activity per mg β-lipoprotein protein in 4 of 5 cases.
P. Bedding, B. Hood, B. Carlander
openaire +3 more sources
Lipoprotein(a) : new insights into an atherogenic lipoprotein
The Clinical Investigator, 1994Lipoprotein(a) constitutes a macromolecular complex in human plasma that combines structural features from the blood clotting and the lipoprotein systems. Aside from the discovery of lipoprotein(a) [Lp(a)] as a potential independent risk factor for premature cardiovascular disease its physiological role and activity remains obscure.
Bartens, Werner, Wanner, Christoph
openaire +3 more sources
JAMA
This JAMA Insights discusses lipoprotein(a), including factors associated with elevated lipoprotein(a) levels, how to manage them, and atherosclerotic cardiovascular disease risk.
Samia, Mora, Florian, Kronenberg
openaire +2 more sources
This JAMA Insights discusses lipoprotein(a), including factors associated with elevated lipoprotein(a) levels, how to manage them, and atherosclerotic cardiovascular disease risk.
Samia, Mora, Florian, Kronenberg
openaire +2 more sources
Lipoprotein(a) and atherogenesis
Trends in Cardiovascular Medicine, 1994Lipoprotein(a) is a major inherited risk factor for atherosclerosis. Many of its activities depend on its plasminlike component, apolipoprotein(a). In vitro studies suggest that apolipoprotein(a) could enhance lipid deposition through binding to sites in the vessel wall, interfere with fibrinolysis, and modulate smooth muscle cell activity.
Richard M. Lawn, Alexander C. Liu
openaire +3 more sources
Current Opinion in Lipidology, 2016
Purpose of review Currently, different methods for extracorporeal elimination of atherogenic apolipoprotein B100 containing lipoprotein particles are used in clinical practice. Most of them effectively remove both lipoprotein(a) [Lp(a)] and LDL.
Olga I. Afanasieva+2 more
openaire +2 more sources
Purpose of review Currently, different methods for extracorporeal elimination of atherogenic apolipoprotein B100 containing lipoprotein particles are used in clinical practice. Most of them effectively remove both lipoprotein(a) [Lp(a)] and LDL.
Olga I. Afanasieva+2 more
openaire +2 more sources